158 related articles for article (PubMed ID: 36641751)
21. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.
Hata AN; Rowley S; Archibald HL; Gomez-Caraballo M; Siddiqui FM; Ji F; Jung J; Light M; Lee JS; Debussche L; Sidhu S; Sadreyev RI; Watters J; Engelman JA
Oncogene; 2017 Nov; 36(47):6581-6591. PubMed ID: 28783173
[TBL] [Abstract][Full Text] [Related]
22. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
[No Abstract] [Full Text] [Related]
23. Oncogenic
Kim MP; Li X; Deng J; Zhang Y; Dai B; Allton KL; Hughes TG; Siangco C; Augustine JJ; Kang Y; McDaniel JM; Xiong S; Koay EJ; McAllister F; Bristow CA; Heffernan TP; Maitra A; Liu B; Barton MC; Wasylishen AR; Fleming JB; Lozano G
Cancer Discov; 2021 Aug; 11(8):2094-2111. PubMed ID: 33839689
[TBL] [Abstract][Full Text] [Related]
24. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
25. Genome-Wide CRISPR Screen for Essential Cell Growth Mediators in Mutant KRAS Colorectal Cancers.
Yau EH; Kummetha IR; Lichinchi G; Tang R; Zhang Y; Rana TM
Cancer Res; 2017 Nov; 77(22):6330-6339. PubMed ID: 28954733
[TBL] [Abstract][Full Text] [Related]
26. Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.
Wang Z; Kang B; Gao Q; Huang L; Di J; Fan Y; Yu J; Jiang B; Gao F; Wang D; Sun H; Gu Y; Li J; Su X
Cancer Sci; 2021 Sep; 112(9):3895-3910. PubMed ID: 34185934
[TBL] [Abstract][Full Text] [Related]
27. BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer.
Bartolini A; Cardaci S; Lamba S; Oddo D; Marchiò C; Cassoni P; Amoreo CA; Corti G; Testori A; Bussolino F; Pasqualini R; Arap W; Corà D; Di Nicolantonio F; Marchiò S
Clin Cancer Res; 2016 Oct; 22(19):4923-4933. PubMed ID: 27143691
[TBL] [Abstract][Full Text] [Related]
28. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer.
Wang Y; Li N; Jiang W; Deng W; Ye R; Xu C; Qiao Y; Sharma A; Zhang M; Hung MC; Lin SH
Clin Cancer Res; 2018 Nov; 24(22):5744-5756. PubMed ID: 30068711
[No Abstract] [Full Text] [Related]
29. Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?
Hasbullah HH; Musa M
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769370
[TBL] [Abstract][Full Text] [Related]
30. Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae.
Kalimutho M; Bain AL; Mukherjee B; Nag P; Nanayakkara DM; Harten SK; Harris JL; Subramanian GN; Sinha D; Shirasawa S; Srihari S; Burma S; Khanna KK
Mol Oncol; 2017 May; 11(5):470-490. PubMed ID: 28173629
[TBL] [Abstract][Full Text] [Related]
31. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
[TBL] [Abstract][Full Text] [Related]
32. P21WAF1/CIP1 expression in colorectal carcinomas is related to Kras mutations and prognosis.
Mitomi H; Ohkura Y; Fukui N; Kanazawa H; Kishimoto I; Nakamura T; Yokoyama K; Sada M; Kobayashi K; Tanabe S; Saigenji K
Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):883-9. PubMed ID: 17873613
[TBL] [Abstract][Full Text] [Related]
33. Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa.
de Bruijn MT; Raats DA; Hoogwater FJ; van Houdt WJ; Cameron K; Medema JP; Borel Rinkes IH; Kranenburg O
Br J Cancer; 2010 Apr; 102(8):1254-64. PubMed ID: 20354524
[TBL] [Abstract][Full Text] [Related]
34. Small G proteins Rac1 and Ras regulate serine/threonine protein phosphatase 5 (PP5)·extracellular signal-regulated kinase (ERK) complexes involved in the feedback regulation of Raf1.
Mazalouskas MD; Godoy-Ruiz R; Weber DJ; Zimmer DB; Honkanen RE; Wadzinski BE
J Biol Chem; 2014 Feb; 289(7):4219-32. PubMed ID: 24371145
[TBL] [Abstract][Full Text] [Related]
35. Activation Of Wild-Type Hras Suppresses The Earliest Stages Of Pancreatic Cancer.
Weyandt J
Redox Biol; 2015 Aug; 5():414. PubMed ID: 28162272
[TBL] [Abstract][Full Text] [Related]
36. Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer.
Zhou Q; Peng Y; Ji F; Chen H; Kang W; Chan LS; Gou H; Lin Y; Huang P; Chen D; Wei Q; Su H; Liang C; Zhang X; Yu J; Wong CC
Nat Commun; 2023 Aug; 14(1):4677. PubMed ID: 37542037
[TBL] [Abstract][Full Text] [Related]
37. A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution.
Anderson GR; Winter PS; Lin KH; Nussbaum DP; Cakir M; Stein EM; Soderquist RS; Crawford L; Leeds JC; Newcomb R; Stepp P; Yip C; Wardell SE; Tingley JP; Ali M; Xu M; Ryan M; McCall SJ; McRee AJ; Counter CM; Der CJ; Wood KC
Cell Rep; 2017 Jul; 20(4):999-1015. PubMed ID: 28746882
[TBL] [Abstract][Full Text] [Related]
38. Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer.
Pek M; Yatim SMJM; Chen Y; Li J; Gong M; Jiang X; Zhang F; Zheng J; Wu X; Yu Q
Oncogene; 2017 Aug; 36(35):4975-4986. PubMed ID: 28459468
[TBL] [Abstract][Full Text] [Related]
39. Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models.
Zhou X; Zhao J; Zhang JV; Wu Y; Wang L; Chen X; Ji D; Zhou GG
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578339
[TBL] [Abstract][Full Text] [Related]
40. NG25, a novel inhibitor of TAK1, suppresses KRAS-mutant colorectal cancer growth in vitro and in vivo.
Ma Q; Gu L; Liao S; Zheng Y; Zhang S; Cao Y; Zhang J; Wang Y
Apoptosis; 2019 Feb; 24(1-2):83-94. PubMed ID: 30515612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
